MRKQ3 20261/4Estimate vs Actual
Earnings per Share
$2.49
+ 19.1% vs Estimate
Surprise as recorded in the analysis; the estimate itself is not on the calendar.
Merck & Co Q3 2026 · Story
Read the quarter card by card, ready to share.
MRKQ3 20261/4MRKQ3 20262/4Guidance
Full-Year Revenue
- Company Guidance
- 66.8 – 67.3 billion
- Market Estimate
- 67.04 billion
In Line ✓
Full-Year Adjusted EPS
- Company Guidance
- 2.77 – 2.82 $
- Market Estimate
- 2.65 $
5.5% Above Estimate ▲
Adjusted Gross Margin
- Company Guidance
- 81%
Flat
MRKQ3 20263/4In 30 Seconds
Revenue of $18.09 billion beat estimates by 4.5%, and adjusted EPS of $2.49 beat by 19.1%.
- Full-year EPS guidance rose to $2.77-2.82, but about $550 million of revenue came from purchase timing that will unwind.
- The stock rose 4.9% intraday on strong Keytruda Qlex and Winrevair sales and the ESMO data.
First point of the analysis's “In 30 Seconds”.
Full AnalysisMRKQ3 20264/4Score
72/ 100
ViewBUY
Not Investment Advice